Sensus Healthcare, Inc. (SRTS) Tops Q4 EPS by 2c, Revenues Beat

Sensus Healthcare, Inc. (NASDAQ: SRTS) reported Q4 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $8.08 million versus the consensus estimate of $7.55 million.

• Continued double-digit growth with revenues of $8.1 million, up 25%
• Net income of $0.1 million, or $0.01 per share, compared to $(0.4) million net loss, or $(0.03) per share
• Adjusted EBITDA, a non-GAAP financial measure, also turned positive at $0.4 million, compared with $(0.2) million
• Shipped 27 systems, including 15 feature-rich, premium-priced SRT-100 Vision™ systems
• Shipped three SRT-100+™ systems following clearance by the U.S. Food and Drug Administration (FDA) in August
• Shipped two SRT-100™ systems to China
• Ended the year with $15.4 million in cash and investments
• First worldwide shipment of Sculptura™ (IORT) to UPenn – Perelman Center

"Our record fourth quarter financial results continue the steady business momentum and double-digit revenue growth we have been reporting consistently since our initial public offering in 2016," said Joe Sardano, Chairman and Chief Executive Officer. "I am very pleased with the achievement of our short- and long-term goals to date and we expect to build on this momentum in the years ahead."

For earnings history and earnings-related data on Sensus Healthcare, Inc. (SRTS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c